LIB Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Ohio, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
5375 Medpace Way, Cincinnati, Ohio, 4522...Phone Number
(800) 345-2032Website
www.libtherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About LIB Therapeutics
LIB Therapeutics is a privately held, commercial-stage biopharmaceutical company focused on developing novel therapies for cardiovascular disease and familial hypercholesterolemia. Their primary product, lerodalcibep, is a third-generation PCSK9 inhibitor designed to provide a convenient, once-monthly subcutaneous dose to help patients achieve lower LDL-C levels. The company aims to address the needs of millions of patients worldwide suffering from atherosclerotic cardiovascular disease and those with severe inherited high cholesterol. Founded in 2015, LIB Therapeutics is committed to expanding treatment options and improving patient outcomes in the field of cardiovascular health.Explore more
LIB Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is LIB Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on LIB Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Click to see if LIB Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at LIB Therapeutics
Funding: Get notified immidiatlly once LIB Therapeutics has new funding data
Check out if LIB Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
LIB Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when LIB Therapeutics launches new products
Check if LIB Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined LIB Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to LIB Therapeutics
Compare insights from companies similar to LIB Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
LIB Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
LIB Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about LIB Therapeutics.
LIB Therapeutics Tech Stack
A closer look at the technologies used by LIB Therapeutics
See more technologies
Most Recent Scoops
Person-Based
Left Company
Executive Move
Executive Moves, Left Company
Project
Product Development, Intellectual Property, Governmental Affairs & Regulation, Medical Research, Pharmaceuticals, Clinical Operations, Regulations
Person-Based
Project
Compliance, Legal Affairs, Pharmaceuticals, Healthcare Technology, Regulations
LIB Therapeutics News & Media
Everest Medicines Announces that Licensing Partner LIB Therapeutics has Received U.S. FDA Approval of LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol
SHANGHAI, Dec. 17, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has approved LEROCHOL™ (lerodalcibep-liga) injection from LIB Therapeutics, for subcutaneous use as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adLIB Therapeutics Announces Key Results from Presentations at 2025 European Atherosclerosis Society Meeting in Glasgow May 5-6
CINCINNATI--(BUSINESS WIRE)--LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company advancing Lerodalcibep (LeroChol®), a novel, monthly, small dose third-generation PCSK9 inhibitor today announced results presented at the May 5-7 2025 European Atherosclerosis Society meeting in Glasgow. LERODALCIBEP ADJUDICATED CARDIOVASCULAR EVENTS IN A PRE-DEFINED POOLED ANALYSIS OF THREE LARGE LONG TERM PHASE III STUDIES – Dr David Kallend May 5th As part of the safety analysis,LIB Therapeutics Announces FDA Acceptance of Biologics License Application for Lerodalcibep to Lower LDL-Cholesterol Across Broad Patient Population
CINCINNATI--(BUSINESS WIRE)--LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) of Lerodalcibep to reduce low-density lipoprotein cholesterol (LDL-C) for the treatment of patients with atherosclerotic cardiovascular disease (ASCVD), or very high or high risk of ASCVD, and primary hyperlipidemia, including heterozygous, and those 10 years orLIB Therapeutics Announces Publication of Phase 3 Study of Lerodalcibep in Homozygous Familial Hypercholesterolemia (HoFH) in Lancet Diabetes & Endocrinology
CINCINNATI--(BUSINESS WIRE)--LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company advancing Lerodalcibep, a novel, third-generation PCSK9 inhibitor today announced the publication of Phase 3 LIBerate-HoFH study of Lerodalcibep in a globally diverse homozygous familial hypercholesterolemia (HoFH) population was published in Lancet Diabetes & Endocrinology (Raal, F.J. et al, 2025). The LIBerate-HoFH study assessed the safety and efficacy of monthly lerodalcibep
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding LIB Therapeutics
Sign Up For FreeTo access detailed company insights
LIB Therapeutics is a privately held, commercial-stage biopharmaceutical company focused on developing novel therapies for cardiovascular disease and familial hypercholesterolemia. Their primary product, lerodalcibep, is a third-generation PCSK9 inhibitor designed to provide a convenient, once-monthly subcutaneous dose to help patients achieve lowe... Read More
